Since daraxonrasib's FDA approval, I have enjoyed reading my mentor, Dr. Robert Mayer's words to @CancerHistProj about pancreatic cancer: decades of "swings, misses, foul balls, and finally a direct hit." That's what sustained NCI investment looks like: shorturl.at/sTItt

September is #ProstateCancerAwarenessMonth! 💙From precision diagnostics and targeted therapies to telehealth exercise programs, Alliance clinical trials are driving the next generation of cancer care. Learn more about our current trials at 👇 bit.ly/Prostate2026 #pcsm

Thrilled to have joined @DanaFarber and to be working with an inspiring leader in oncology, @DrChoueiri. Delighted to serve as a faculty medical oncologist and Co-Director of the @Harvard Cancer Consortium #ProstateCancer Program. Excited for this new chapter!

Now enrolling! The Alliance A032303 (GAIN-BCG) trial is testing whether adding gemcitabine, a chemotherapy drug, to BCG, a #bladdercancer immunotherapy, can help prevent high-grade non-muscle-invasive bladder cancer from coming back. Visit bit.ly/Alliance-GAIN-BCG #NCI #NCTN

Now enrolling! @ThomasHopeMD of @UCSFHospitals and Deaglan McHugh of @MSKCancerCenter lead Alliance A032304 (RECIPROCAL), a phase III study to optimize targeted radiation therapy to minimize side effects while preserving efficacy in prostate cancer bit.ly/AllianceA032304

Once a Cane, always a Cane. 🙌   For some families, becoming a Cane runs in the family! 🧡💚   This week, Hurricanes legend Ed Reed, B.L.A. ’02, and UM parent, welcomed our newest Canes to the UM family - the children and grandchildren of University of Miami alumni who are starting at the U this fall.   At the annual legacy welcome reception, Ed reminded us what it truly means to be a Cane for life. Joined by Executive Vice President for Academic Affairs & Provost Joel Samuels; Senior Vice President for Student Affairs and Alumni Engagement Pat Whitely, Ed.D. ’94; UM Alumni Association Board of Directors President Darren Dupriest, B.B.A. ’91; President-Elect David Mullings, B.S. ’00, M.B.A. ’03; among other university leaders, the evening celebrated multi-generations of Canes all united by one bond – the U.   We can’t wait to see the impact the next generation of Canes will have and watch the legacy continue. #CanesForLife #CaneKickOff2026 #HurricaneLegend

Dana-Farber Brigham Cancer Center has been recognized as the Best Hospital for Cancer in Massachusetts and ranked #3 in the nation by @usnews. Learn more: bit.ly/3TDL9Qi

15 Posts Not To Miss From the 2026 Bladder Cancer Advocacy Network Think Tank @BladderCancerUS @DrOmarMian @FaltasLab @UroDocAsh @katy_beckermann @Parminder1699 @LauraBukavinaMD @PGrivasMDPhD @DrKarineTawagi @apolo_andrea @bergsa83 @akfsurgeon @BrendanGuercio @shilpaonc @DrAndreKydd oncodaily.com/not-to-miss/bc…

🎉 Registration for our 2026 International Kidney Cancer Symposium (IKCS): North America is open! #IKCSNA26 Early registration rates available now. We're excited to welcome you to Dallas! Reserve your spot to join us 👉 web.cvent.com/event/885b2adb…

Great breakout session on treatment de-intensification for #bladdercancer, less is more! #BCANTT26 The emphasis on bladder preservation and evolving risk-adapted role of radical therapies is great for patients. @KMittalmd @snseyedinMD @bergsa83 @abhinav__khanna @BladderCancerUS

#BCANTT26 discussion of ctDNA in clinical trials @alantanmd @LauraBukavinaMD @mouwlab @DrJohnSfakianos essential for personalized treatment selection, monitoring & treatment Ultra sensitive ctDNA = future in solid tumors @TempusAI @NateraOncology assays discussed

Looking forward to @BladderCancerUS BCAN Think Tank this week; presenting at the “Less Is More” breakout session chaired by @bergsa83 and @ClintonTim Excited to discuss how evidence is reshaping treatment de-escalation #BCANThinkTank @Parminder1699 @PGrivasMDPhD @MonikaJoshimd

@DrRosenbergMSK discusses EVP perioperative, overtreatment and undertreatment certainly exists, we just need to study this more. pCR, is this enough to de-escalate the adjuvant portion? VOLGA will help answer this as well. @koshkin85 @UroDocAsh @JoshMeeks @SimaPorten eloquently add to this discussion.

Today's News: Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer ir.revmed.com/node/13261/pdf @RevMedicines @DavidHongMD @kevansf @GarridoLagunaMD @Sandra_Misale

Now enrolling! BCG (a bladder immunotherapy) is standard for non-muscle invasive bladder cancer. For cancer that returns after BCG, Alliance A032103 (GAIN) trial tests adding gemcitabine—a chemo drug—to BCG to prevent recurrence. Learn more: bit.ly/Alliance-GAIN-BCG #BladderCancer

Great fireside chat @kidneycan with Drs Akins , Belldegrun and @DrChoueiri #KCRS26 Discussing the past and future of kidney cancer !

Now, the combo of EV-Pembro is @US_FDA approved for all muscle-invasive bladder cancer @OncoAlert @AUC3_Official @Merck @BladderCancerUS @OncoBellmunt @bergsa83 @mouwlab fda.gov/drugs/resources-info…

Our Women in RCC ✨ Summer Webinar ✨ is one week away! Register now 🔗 bit.ly/4vzPPVq 🗓️ Jul 16 | 6:30 PM ET 🔬 Key #kidneycancer highlights from recent scientific meetings 👩‍🏫 Presentations by next-gen female leaders 🗣️ Interactive attendee discussion

@ALLIANCE_org & Alliance Foundation Trials presented research spanning breast, GI, GU, thoracic, neuro-oncology, and survivorship data. Key takeaways: 1️⃣ Tech Integration 2️⃣ Biomarker-Driven Strategies 3️⃣ Focus on Lifestyle & Quality of Life: #ASCO26 bit.ly/AllianceAtASCO26

When I left Greece in 2007 pursuing academic career in US, envisioned returning with colleagues from around globe connecting them with Greek colleagues & showing our hospitality! We continue yearly! @tompowles1 @brian_rini @BradMcG04 @bergsa83 @DrOmarMian @ChadTangMD @OncoAlert